About this item:

432 Views | 454 Downloads

Author Notes:

Correspondence: Dean P. Jones; Email: dpjones@emory.edu

Authors' Contributions: Conceived and designed the experiments: DPJ, YHP, BR and JRR.

Performed the experiments: YHP, VT and DIW.

Contributed reagents/materials/analysis tools: BR, DPJ and KU.

Wrote the manuscript: JRR, KU, BR, YHP, SLR and DPJ.

Gathered clinical data and serum samples: BR and SLR.

Analyzed the data: JRR, KU, DIW, YHP and KL.

Analyzed metabolomics data: JRR, KU, VT, YHP, FHS and DPJ.

Reviewed and revised final manuscript: JRR, KU, YHP, VT, FHS, BR, SLR and DPJ.

Disclosures: The authors have declared that no competing interests exist.


Research Funding:

The following research was supported by the grants from the National Institutes of Health and the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript: K99ES022266, P01ES016731, R01ES010544, P01ES016732, R01NS038367, U54ES012078.

This work was also supported by a pilot grant from the American Parkinson's Disease Association.

Serum Metabolomics of Slow vs. Rapid Motor Progression Parkinson's Disease: a Pilot Study

Journal Title:



Volume 8, Number 10


, Pages e77629-e77629

Type of Work:

Article | Final Publisher PDF


Progression of Parkinson’s disease (PD) is highly variable, indicating that differences between slow and rapid progression forms could provide valuable information for improved early detection and management. Unfortunately, this represents a complex problem due to the heterogeneous nature of humans in regards to demographic characteristics, genetics, diet, environmental exposures and health behaviors. In this pilot study, we employed high resolution mass spectrometry-based metabolic profiling to investigate the metabolic signatures of slow versus rapidly progressing PD present in human serum. Archival serum samples from PD patients obtained within 3 years of disease onset were analyzed via dual chromatography-high resolution mass spectrometry, with data extraction by xMSanalyzer and used to predict rapid or slow motor progression of these patients during follow-up. Statistical analyses, such as false discovery rate analysis and partial least squares discriminant analysis, yielded a list of statistically significant metabolic features and further investigation revealed potential biomarkers. In particular, N8-acetyl spermidine was found to be significantly elevated in the rapid progressors compared to both control subjects and slow progressors. Our exploratory data indicate that a fast motor progression disease phenotype can be distinguished early in disease using high resolution mass spectrometry-based metabolic profiling and that altered polyamine metabolism may be a predictive marker of rapidly progressing PD.

Copyright information:

© 2013 Roede et al.

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Export to EndNote